Clinical trials in Clermont Ferrand – page 18

651 clinical trials in Clermont Ferrand, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Clermont Ferrand at a glance

651

clinical trials

Research sites3

Quick filters

651 trials in Clermont Ferrand

Open in trial search

Neoplasm

Recruiting

Study of Dostarlimab for Patients with Advanced or Metastatic Non-Colorectal/Non-Endometrial Cancer with dMMR/MSI, Compared to Standard Drug Combination

Registered drugNo placebo

Study of Dostarlimab for Patients with Advanced or Metastatic Non-Colorectal/Non-Endometrial Cancer with dMMR/MSI, Compared to Standard Drug Combination

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Unicancer

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study of V940 and Pembrolizumab for Patients with Resected Stage II, IIIA, IIIB Non-Small Cell Lung Cancer

Registered drug

Study of V940 and Pembrolizumab for Patients with Resected Stage II, IIIA, IIIB Non-Small Cell Lung Cancer

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Mrna-4157
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Aortic valve stenosis

Recruiting

Study on Short vs. Long Antiplatelet Therapy with Aspirin for Adults After TAVI for Symptomatic Aortic Stenosis

Registered drugNo placebo

Study on Short vs. Long Antiplatelet Therapy with Aspirin for Adults After TAVI for Symptomatic Aortic Stenosis

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Acetylsalicylic Acid
Sponsor:Centre Hospitalier Universitaire De Caen Normandie

Contact Research Centre

Non-small cell lung cancer+1

Recruiting

Study of LN-145 (Tumor Infiltrating Lymphocytes) in patients with metastatic non-small-cell lung cancer

Registered drugNo placebo

Study of LN-145 (Tumor Infiltrating Lymphocytes) in patients with metastatic non-small-cell lung cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Aldesleukin
Sponsor:Iovance Biotherapeutics Inc.

Contact Research Centre

Colorectal cancer+2

Recruiting

Study on the Safety and Effects of [68Ga]Ga-DPI-4452 and [177Lu]Lu-DPI-4452 in Patients with Advanced or Metastatic Solid Tumors

Registered drugNo placebo

Study on the Safety and Effects of [68Ga]Ga-DPI-4452 and [177Lu]Lu-DPI-4452 in Patients with Advanced or Metastatic Solid Tumors

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Acetazolamide
Sponsor:ITM Oncologics GmbH

Contact Research Centre

Neoplasm malignant+7

Recruiting

Study on the Safety and Effects of XL092 with Nivolumab, Ipilimumab, and Relatlimab for Patients with Advanced Solid Tumors

Registered drugNo placebo

Study on the Safety and Effects of XL092 with Nivolumab, Ipilimumab, and Relatlimab for Patients with Advanced Solid Tumors

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Ipilimumab
Sponsor:Exelixis Inc.

Contact Research Centre

Hormone-dependent prostate cancer

Recruiting

Study on the Effectiveness of Lutetium (177Lu) Vipivotide Tetraxetan with Standard Treatment for Men with Metastatic Hormone-Sensitive Prostate Cancer

Registered drugNo placebo

Study on the Effectiveness of Lutetium (177Lu) Vipivotide Tetraxetan with Standard Treatment for Men with Metastatic Hormone-Sensitive Prostate Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:Unicancer

Contact Research Centre

Pulmonary embolism+7

Recruiting

Study on Rosuvastatin for Reducing Blood Clots in Patients with Deep Vein Thrombosis or Pulmonary Embolism

Registered drug

Study on Rosuvastatin for Reducing Blood Clots in Patients with Deep Vein Thrombosis or Pulmonary Embolism

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Rosuvastatin Calcium
Sponsor:Centre Hospitalier Regional Et Universitaire De Brest

Contact Research Centre

Renal cell carcinoma

Recruiting

Study on Cabozantinib and Drug Combination for Untreated Metastatic Renal Cell Carcinoma in Intermediate and Poor Risk Patients

Registered drugNo placebo

Study on Cabozantinib and Drug Combination for Untreated Metastatic Renal Cell Carcinoma in Intermediate and Poor Risk Patients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Axitinib
Sponsor:Institut Gustave Roussy

Contact Research Centre

Neuroendocrine tumour

Recruiting

Study on Retreatment with Lutetium (177Lu) Oxodotreotide for Patients with Intestinal Neuroendocrine Tumors

Registered drugNo placebo

Study on Retreatment with Lutetium (177Lu) Oxodotreotide for Patients with Intestinal Neuroendocrine Tumors

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:L-Arginine Hydrochloride
Sponsor:Institut Regional Du Cancer De Montpellier

Contact Research Centre

Perinatal depression

Recruiting

Study on Treating Anemia After Cesarean with Ferric Carboxymaltose or Oral Iron in Women with Moderate Iron Deficiency Anemia

Registered drugNo placebo

Study on Treating Anemia After Cesarean with Ferric Carboxymaltose or Oral Iron in Women with Moderate Iron Deficiency Anemia

Registered drugNo placebo

France

Participants:18–64 years
Substances:Ascorbic Acid
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Rectal cancer

Recruiting

Study on Managing Locally-Advanced Rectal Cancer with Oxaliplatin, Fluorouracil, and Irinotecan Hydrochloride for Patients Responding Well to Initial Chemotherapy

Registered drugNo placebo

Study on Managing Locally-Advanced Rectal Cancer with Oxaliplatin, Fluorouracil, and Irinotecan Hydrochloride for Patients Responding Well to Initial Chemotherapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Institut Regional Du Cancer De Montpellier

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Clermont Ferrand

What the registry says about research in the country

01 Gastrointestinal Research

Innovative studies focusing on inflammatory bowel diseases including groundbreaking trials examining fecal microbiota transplantation in both Crohn's disease and ulcerative colitis. Research aims to evaluate new therapeutic approaches for patients with moderate to severe conditions.

Crohn's Disease Management
Ulcerative Colitis Treatment
Microbiota-based Therapies

These trials are exploring alternative treatment pathways for patients who have not responded to conventional therapies.

02 Oncology Studies

Comprehensive research in multiple myeloma and various cancer types, including innovative treatments for esophageal squamous cell carcinoma and pleural mesothelioma. Studies evaluate new therapeutic combinations and maintenance strategies.

Blood Cancer Treatments
Prostate Cancer Therapy
Biliary Tract Cancer Research

Focus on improving patient outcomes through targeted therapies and immunological approaches.

03 Autoimmune Conditions

Advanced research into rheumatoid arthritis and multiple sclerosis, investigating optimized treatment protocols and maintenance therapies. Studies aim to improve long-term disease management and patient quality of life.

Multiple Sclerosis Treatments
Rituximab Optimization
Antibody-based Therapies

Emphasis on developing more effective and tolerable treatment regimens.

Back to France All countries